English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The leishmaniasis is a group of diseases with a broad range of clinical manifestations caused by several species of parasites belonging to the genus Leishmania. LL-37/hCAP18, the only cathelicidin in human, is expressed as an 18-kDa preproprotein. The most prominent function of cathelicidins is their ability to inhibit propagation of a diverse range of microorganisms, which occurs at a micromolar range. Aim: The study was aimed to evaluate the LL37 plasma level in Leishmania Sudanese patients. Materials and Methods: In a case-control study, three hundred subjects were enrolled (200 as case and 100 controls). Five ml. of venous blood was collected in EDTA container, then plasma was obtained and stored frozen at -80ºC. LL 37 was estimated using competitive ELISA. The data were analyzed using SPSS version 21. Results: The results revealed that 115 (57%) of Leishimania patients were male and 85 (43%) were female. Plasma LL 37 level was significantly increased in Leishmania patients (1.30±0.71) compared to the control (0.21±0.20) with (p-value 0.000). Conclusion: Leishmania patients had higher levels of plasma LL37, suggesting effective anti-microbial immunity process enhancing healing of cutaneous leishmaniasis. Keywords:  Cathelicidins; LL37, Innate Immunity, Leishmania , Sudan.

Evaluation of LL 37 Lipoprotein as Innate Immunity Marker among Sudanese Patients Cutaneous Leishmania